GVHD is a lifelong concern for blood cancer survivors

Nearly 200,000 Americans are diagnosed with blood cancers such as leukemia and lymphoma every year. For these individuals, hematopoietic cell transplantation offers hope for survival. Unfortunately, transplant recipients remain at lifetime risk of Graft-Versus-Host disease (GVHD), a deadly condition with approximately 70% incidence.

GVHD is difficult to manage with current tools

GVHD manifests in the skin as sclerosis, providing a potential biomarker to detect the disease and manage treatment. However, current methods – manual palpitation, compression, suction – are imprecise and exhibit too much inter-provider variability to be clinically useful.

A new standard in GVHD care

Bullseye™ makes quantitative measurements of skin elasticity, and is being designed for easy use by any member of the clinical staff. These data may assist in the clinical assessment of skin, facilitating earlier detection of GVHD, accurate staging of disease progression or characterization of an individual's response to therapy.*

*This statement has not been evaluated by the FDA, and Bullseye is not cleared for sale in the USA or intended for clinical diagnostic use.

Many therapies aim to improve skin elasticity

Skin elasticity is driven by the amount of collagen in the dermis. As we age, the collagen degrades, and the skin loses elasticity and becomes saggy. There are various topicals, injectables and non-invasive procedures that promise to rebuild collagen.

It is difficult to choose the right therapy at the right time

Most people address skin aging by waiting until they can see wrinkles and fine lines. At this point, the ideal window for intervention has passed. Additionally, when choosing a therapy, it is unclear which treatment is ideal for them.

Bullseye provides transparency to anti-aging skincare

With Bullseye's easy quantification of skin elasticity and thickness, changes in skin structure may be detectable before they result in saggy skin. Understand how each individual's skin is aging may be helpful to select the appropriate anti-aging therapy, guide application, or monitor the therapeutic effect for optimal results.

MicroElastic is building the data-driven future of precision skincare by developing a handheld device that uses ultrasound to instantly quantify the physical properties of skin, replacing subjective manual palpation that is currently used in clinical practice. Our platform will unlock the potential of skin properties for various applications, ranging from precision medicine to consumer skincare.

Developed at Duke University and protected by three international patents (pending), MicroElastic's Bullseye™ technology takes proven science and shrinks it down for the point-of-care. By taking advantage of a phenomenon called Constructive Shearwave Interference (CSI), Bullseye™ devices use focused ultrasound to generate vibrations around the edge of a "virtual biopsy core", and measure those propagating vibrations as they reach they core's center. The self-amplification of these signals and unique geometry lets us safely generate and easily measure these vibrations, enabling a portable form factor fit for any clinical setting.

January 29th, 2021

MicroElastic has achieved its most important commercial validation to date, by fully committing its entire fleet of demo devices to clinical studies with strategic partners. The initial engagements will last several months and will yield important evidence for the utility of our technology in the context of anti-aging applications.

October 5th, 2020

Our STTR-funded clinical study is now underway at Duke Health. This study will both build a baseline normagram of skin elasticity in healthy volunteers, and correlate our noninvasive measurements of elasticity against invasive gold-standard scoring of skin sclerosis via biopsy in patients with sclerotic skin disease, in particular patients with Graft-Versus-Host-Disease.

July 29th, 2020

MicroElastic is excited to announce that we are launching a demo fleet of Bullseye devices in September. We are currently arranging clinical studies with partners in the skincare industry to evaluate the effects of several therapies on skin elasticity. Please contact us if you are interested in a virtual demo!

January 24th, 2020

MicroElastic will be attending the American Academy of Dermatology Annual Meeting to share updates on our technology and clinical data, as well as engage with potential strategic partners. Please reach out directly if you are attending and would like to arrange a meeting. The event will be held March 20-24 at the Colorado Convention Center in Denver, CO.

January 14th, 2020

MicroElastic was invited to deliver a 4-minute pitch presentation at the Venture Connect Summit, hosted by the Council for Entrepreneurial Development, and considered the premier life science event in the southeast. The event will be held March 17-19 at the Raleigh Convention Center in Raleigh, NC.

January 2nd, 2020

MicroElastic welcomes Kyle Langdell as Chief Business Officer. Kyle will be leading the marketing, strategy, and fundraising efforts and brings over five years of experience in the medical device industry. Kyle holds an MBA from Carnegie Mellon University and a BS in Biomedical Engineering from Duke University.